A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease
This MCED test preferentially detects high-grade, clinically significant PCa. Use in population-based screening programs in addition to standard-of-care screening is unlikely to exacerbate overdiagnosis of indolent PCa.
Authors
- Eric A. Klein (ORCID: https://orcid.org/0000-0002-1783-0698)
- Jeffrey M. Venstrom
- Jordan J. Karlitz (ORCID: https://orcid.org/0000-0001-5686-7365)
- Brandon A. Mahal (ORCID: https://orcid.org/0000-0001-5406-3232)
- Earl Hubbell (ORCID: https://orcid.org/0000-0001-7301-3759)
- Alexander W. Wyatt (ORCID: https://orcid.org/0000-0003-2399-0329)
- Matthew Margolis (ORCID: https://orcid.org/0000-0001-9998-7543)
- Cheng Chen (ORCID: https://orcid.org/0000-0002-0309-9777)
- John Abran (ORCID: https://orcid.org/0000-0003-3592-349X)
Institutions
- University of British Columbia (CA)
- University of Miami (US)
- Menlo School (US)
- Grail (United States) (US)
- Sylvester Comprehensive Cancer Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1200/po.24.00269
- Citations
- 12
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.42
Funders
- U.S. Department of Defense
- Prostate Cancer Foundation
- Pfizer
- AstraZeneca
- Sanofi
- Regeneron Pharmaceuticals
- Genentech
- EMD Serono
- Foundation Medicine
- DOD Prostate Cancer Research Program